Market openNon-fractional

Abcellera Biologics/ABCL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Abcellera Biologics

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Ticker

ABCL

Sector

Healthcare

Trading on

NASDAQ

Industry

Life Sciences Tools and Services

Headquarters

Vancouver, Canada

Employees

586

ABCL Metrics

BasicAdvanced
$797M
Market cap
-
P/E ratio
-$0.51
EPS
0.44
Beta
-
Dividend rate
$797M
0.44
7.761
7.311
6.025
6.515
-9.59%
-12.56%
21.991
0.7
0.83
-6.14
-80.23%
185.73%
-56.38%
-14.31%

What the Analysts think about ABCL

Analyst Ratings

Majority rating from 9 analysts.
Buy

ABCL Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-410.10% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$9.9M
8.79%
Net income
-$41M
-13.80%
Profit margin
-410.10%
-20.77%

ABCL Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 15.79%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.11
-$0.10
-$0.17
-$0.14
-
Expected
-$0.13
-$0.13
-$0.13
-$0.17
-$0.14
Surprise
-15.38%
-25.62%
28.57%
-15.79%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market openNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Abcellera Biologics stock?

Abcellera Biologics (ABCL) has a market cap of $797M as of July 05, 2024.

What is the P/E ratio for Abcellera Biologics stock?

The price to earnings (P/E) ratio for Abcellera Biologics (ABCL) stock is 0 as of July 05, 2024.

Does Abcellera Biologics stock pay dividends?

No, Abcellera Biologics (ABCL) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Abcellera Biologics dividend payment date?

Abcellera Biologics (ABCL) stock does not pay dividends to its shareholders.

What is the beta indicator for Abcellera Biologics?

Abcellera Biologics (ABCL) has a beta rating of 0.44. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Abcellera Biologics stock

Buy or sell Abcellera Biologics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing